COST-EFFECTIVENESS ANALYSIS OF USTEKINUMAB COMPA RED WITH ETANERCEPT FOR THE TREATMENT OF MODERATE TO SEVERE PSORIASIS IN COSTA RICA

被引：1
|
作者：
Obando, C. A. [1 ]
Desanvicente-Celis, Z. [1 ]
Herrera, J. A. [1 ]
Moreira, M. [1 ]
De Castro, J. [1 ]
机构：
[1] Janssen, Panama City, Panama
来源：
VALUE IN HEALTH | 2014年 / 17卷 / 07期
关键词：
D O I：
10.1016/j.jval.2014.08.2120
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PSS22
引用
收藏
页码：A607 / A607
页数：1
相关论文
共 50 条
  • [1] COST EFFECTIVENESS OF TREATMENT WITH ETANERCEPT OR USTEKINUMAB FOR MODERATE TO SEVERE PSORIASIS
    Villacorta, R.
    Hay, J.
    Messali, A.
    [J]. VALUE IN HEALTH, 2012, 15 (04) : A103 - A103
  • [2] A COST-EFFECTIVENESS ANALYSIS OF ETANERCEPT FOR THE TREATMENT OF MODERATE AND SEVERE PSORIASIS IN MEXICO
    Vargas-Valencia, J.
    Sotelo-Guzman, M.
    Mould-Quevedo, J. F.
    Mucino-Ortega, E.
    Galindo-Suarez, R. M.
    [J]. VALUE IN HEALTH, 2011, 14 (03) : A55 - A55
  • [3] COST-EFFECTIVENESS OF USTEKINUMAB VS ETANERCEPT FOR SEVERE PSORIASIS
    Sura, M.
    Avxentyeva, M.
    Omelyanovsky, V
    Zorin, N.
    Hailov, P.
    [J]. VALUE IN HEALTH, 2011, 14 (07) : A506 - A506
  • [4] COST-EFFECTIVENESS OF SECUKINUMAB COMPARED WITH USTEKINUMAB AND ETANERCEPT FOR THE TREATMENT OF MODERATE-TO-SEVERE PLAQUE PSORIASIS IN GREECE
    Tzanetakos, C.
    Kourlaba, G.
    Chatzikou, M.
    Antoniou, C.
    Ioannidis, D.
    Lefaki, I
    Petridis, A.
    Rigopoulos, D.
    Roussaki-Schulze, A.
    Sotiriadis, D.
    Maniadakis, N.
    [J]. VALUE IN HEALTH, 2016, 19 (07) : A569 - A569
  • [5] Cost-effectiveness of secukinumab compared with ustekinumab and etanercept for the treatment of moderate-to-severe plaque psoriasis in Greece
    Tzanetakos, C.
    Kourlaba, G.
    Hatzikou, M.
    Antoniou, C.
    Ioannides, D.
    Lefaki, I.
    Petridis, A.
    Rigopoulos, D.
    Roussaki-Schulze, V.
    Sotiriadis, D.
    Maniadakis, N.
    [J]. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2016, 30 : 61 - 62
  • [6] The cost-effectiveness of ustekinumab for moderate-to-severe psoriasis
    Rouse, Nicole C.
    Farhangian, Michael E.
    Wehausen, Brooke
    Feldman, Steven R.
    [J]. EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2015, 15 (06) : 877 - 884
  • [7] Cost Effectiveness of Moderate to Severe Psoriasis Therapy with Etanercept and Ustekinumab in the United States
    Villacorta, Reginald
    Hay, Joel W.
    Messali, Andrew
    [J]. PHARMACOECONOMICS, 2013, 31 (09) : 823 - 839
  • [8] Cost Effectiveness of Moderate to Severe Psoriasis Therapy with Etanercept and Ustekinumab in the United States
    Reginald Villacorta
    Joel W. Hay
    Andrew Messali
    [J]. PharmacoEconomics, 2013, 31 : 823 - 839
  • [9] Cost-effectiveness of the treatment for moderate to severe psoriasis in Mexico:: Infliximab, etanercept and efalizumab
    Mucino, E.
    Rivas, R.
    Zapata, L.
    [J]. VALUE IN HEALTH, 2008, 11 (03) : A288 - A288
  • [10] MODELING THE COST-EFFECTIVENESS OF USTEKINUMAB FOR MODERATE TO SEVERE PLAQUE PSORIASIS IN US
    Verma, S.
    Dharmarajan, S.
    Yang, Y.
    [J]. VALUE IN HEALTH, 2010, 13 (03) : A147 - A147
12345